Galapagos Expands and Extends Drug Discovery Collaboration with Amgen
News Jan 04, 2007
As Galapagos has reported, the BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen's discovery programs.
Under the terms of the extended agreement, Galapagos will receive an upfront fee of $2.4 million as a payment for 2007 research costs.
Additionally, Galapagos may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses.
The initial collaboration, announced in January 2003, involves the identification of lead candidates against multiple ion channel targets.
According to Galapagos, the agreement announced now expands this collaboration to include all classes of targets, including ion channel, GPCR and kinase targets.
Additionally, the agreement has been expanded to include the supply of BioFocus DPI's compound collection comprising 700,000 synthetic small molecules and its proprietary natural product compound collection containing 145,000 pre-purified subfractions, pure natural products, and semi-synthetic natural products.
"The additional breadth and depth gained by BioFocus DPI's drug discovery offering this year have helped us to expand our strong collaborative relationship with Amgen," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
"We are excited that the potential hits arising from BioFocus DPI's unique library collections could provide promising lead candidates for Amgen's discovery programs over the next two years."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE